Cargando…

Dual effects of a CpG-DNAzyme targeting mutant EGFR transcripts in lung cancer cells: TLR9 activation and EGFR downregulation

Non-small-cell lung cancer (NSCLC) is commonly caused by a mutation in the epidermal growth factor receptor (EGFR) and subsequent aberrant EGFR signaling with uncontrolled kinase activity. A deletion mutation in EGFR exon 19 is frequently observed in EGFR gene mutations. We designed a DNAzyme to sup...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jang, Dahye, Baek, Yu Mi, Park, Hanna, Hwang, Yeo Eun, Kim, Dong-Eun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Society for Biochemistry and Molecular Biology 2018
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5796631/ https://www.ncbi.nlm.nih.gov/pubmed/28893372 http://dx.doi.org/10.5483/BMBRep.2018.51.1.163

Ejemplares similares

BIX01294 inhibits EGFR signaling in EGFR-mutant lung adenocarcinoma cells through a BCKDHA-mediated reduction in the EGFR level
por: Kim, Ji Hye, et al.
Publicado: (2021)

In Vivo TLR9 Inhibition Attenuates CpG-Induced Myocardial Dysfunction
por: Boehm, O., et al.
Publicado: (2013)

Overcoming EGFR T790M-based Tyrosine Kinase Inhibitor Resistance with an Allele-specific DNAzyme
por: Lai, Wei-Yun, et al.
Publicado: (2014)

Lapatinib, a Dual EGFR and HER2 Tyrosine Kinase Inhibitor, Downregulates Thymidylate Synthase by Inhibiting the Nuclear Translocation of EGFR and HER2
por: Kim, Hwang-Phill, et al.
Publicado: (2009)

FAM188B Downregulation Sensitizes Lung Cancer Cells to Anoikis via EGFR Downregulation and Inhibits Tumor Metastasis In Vivo
por: Jang, Eun-Ju, et al.
Publicado: (2021)

Downregulation of death receptor 4 is tightly associated with positive response of EGFR mutant lung cancer to EGFR-targeted therapy and improved prognosis
por: Zhang, Shuo, et al.
Publicado: (2021)

Functional Downregulation of PD-L1 and PD-L2 by CpG and non-CpG Oligonucleotides in Melanoma Cells
por: Kleemann, Johannes, et al.
Publicado: (2022)

TLR9 traffics through the Golgi complex to localize to endolysosomes and respond to CpG DNA
por: Chockalingam, Annapoorani, et al.
Publicado: (2008)

Development of CpG-Oligodeoxynucleotides for Effective Activation of Rabbit TLR9 Mediated Immune Responses
por: Chuang, Tsung-Hsien, et al.
Publicado: (2014)

Immunotherapy of Malignant Glioma by Noninvasive Administration of TLR9 Agonist CpG Nano‐Immunoadjuvant
por: Wei, Jingjing, et al.
Publicado: (2022)

EGFR monoclonal antibody panitumumab inhibits chronic proliferative cholangitis by downregulating EGFR
por: Liu, San-Hu, et al.
Publicado: (2019)

Three-Dimensional Modeling of CpG DNA Binding with Matrix Lumican Shows Leucine-Rich Repeat Motif Involvement as in TLR9-CpG DNA Interactions
por: Choi, Tansol, et al.
Publicado: (2023)

3D modeling of CpG DNA binding with matrix lumican shows leucine-rich repeat motif involvement as in TLR9-CpG DNA interactions
por: Choi, Tansol, et al.
Publicado: (2023)

CpG and Non-CpG Methylation in Epigenetic Gene Regulation and Brain Function
por: Jang, Hyun Sik, et al.
Publicado: (2017)

Expression of EGFR-mutant proteins and genomic evolution in EGFR-mutant transformed small cell lung cancer
por: Zhang, Shi-Ling, et al.
Publicado: (2023)

The content of mutant EGFR DNA correlates with response to EGFR-TKIs in lung adenocarcinoma patients with common EGFR mutations
por: Hung, Ming-Szu, et al.
Publicado: (2016)

Recruitment of hexahydroquinoline as anticancer scaffold targeting inhibition of wild and mutants EGFR (EGFR(WT), EGFR(T790M), and EGFR(L858R))
por: Abo Al-Hamd, Mahmoud G., et al.
Publicado: (2023)

Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR-mutant glioblastoma
por: Makhlin, Igor, et al.
Publicado: (2019)

pDC Activation by TLR7/8 Ligand CL097 Compared to TLR7 Ligand IMQ or TLR9 Ligand CpG
por: Wu, Jing, et al.
Publicado: (2019)

TLR9-mediated ARF6 activation is involved in advancing CpG ODN cellular uptake
por: Wu, Jing-Yiing, et al.
Publicado: (2012)

Route of Administration of the TLR9 Agonist CpG Critically Determines the Efficacy of Cancer Immunotherapy in Mice
por: Nierkens, Stefan, et al.
Publicado: (2009)

CpG oligonucleotides bind TLR9 and RRM-Containing proteins in Atlantic Salmon (Salmo salar)
por: Iliev, Dimitar B, et al.
Publicado: (2013)

The Effect of TLR9 Agonist CpG Oligodeoxynucleotides on the Intestinal Immune Response of Cobia (Rachycentron canadum)
por: Byadgi, Omkar, et al.
Publicado: (2014)

PIKfyve Regulates the Endosomal Localization of CpG Oligodeoxynucleotides to Elicit TLR9-Dependent Cellular Responses
por: Hazeki, Kaoru, et al.
Publicado: (2013)

Synthetic Human TLR9-LRR11 Peptide Attenuates TLR9 Signaling by Binding to and thus Decreasing Internalization of CpG Oligodeoxynucleotides
por: Pan, Xichun, et al.
Publicado: (2016)

Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR-mutant lung cancer
por: Nanjo, Shigeki, et al.
Publicado: (2022)

TRAIL is involved in CpG ODN-mediated anti-apoptotic signals
por: LIM, EUN-JUNG, et al.
Publicado: (2011)

Preservation of methylated CpG dinucleotides in human CpG islands
por: Panchin, Alexander Y., et al.
Publicado: (2016)

Detection of EGFR Mutations in Cerebrospinal Fluid of EGFR-Mutant Lung Adenocarcinoma With Brain Metastases
por: Shi, Liang, et al.
Publicado: (2021)

The influence of tumor heterogeneity on sensitivity of EGFR-mutant lung adenocarcinoma cells to EGFR-TKIs
por: Sun, Li, et al.
Publicado: (2019)

Multiple Immunosuppressive Effects of CpG-c41 on Intracellular TLR-Mediated Inflammation
por: Liu, Wancheng, et al.
Publicado: (2017)

Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC
por: Ju, Jia-Shiuan, et al.
Publicado: (2023)

Prognostic value of quantitative measurement of EGFR mutation using peptide nucleic acid clamping in advanced EGFR mutant non‐small cell lung cancer patients
por: Kim, Insu, et al.
Publicado: (2019)

Suppressive CpG
por: Van Epps, Heather L.
Publicado: (2005)

Factors to preserve CpG-rich sequences in methylated CpG islands
por: Miyahara, Hiroki, et al.
Publicado: (2015)

Outcomes of salvage lung resections in advanced EGFR ‐mutant lung adenocarcinomas under EGFR TKIs
por: Chen, Ying‐Yuan, et al.
Publicado: (2021)

EGFR first- and second-generation TKIs—there is still place for them in EGFR-mutant NSCLC patients
por: Karachaliou, Niki, et al.
Publicado: (2019)

Continuous Vaginal Bleeding Induced By EGFR-TKI in Premenopausal Female Patients With EGFR Mutant NSCLC
por: Yu, Min, et al.
Publicado: (2022)

Prognostic Significance of CpG Island Methylator Phenotype in Colorectal Cancer
por: Joo, Young-Eun
Publicado: (2015)

Aberrant CpG Islands Hypermethylation Profiles in Malignant Gliomas
por: Kim, Kwang Ryeol, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_mjrs0bmm48j0kb4so833ivtv58